Immunotherapy of Hepatocellular Carcinoma

Description

In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients. Front Matter ....Pages i-x Vaccine Approaches in Hepatocellular Carcinoma (Maria Tagliamonte, Maria Lina Tornesello, Franco M. Buonaguro, Luigi Buonaguro)....Pages 1-17 Natural Killer Cells in Hepatocellular Carcinoma: Anti-Tumor Effect and Therapeutic Potential (Elisabetta Cariani, Gabriele Missale)....Pages 19-38 Antigen-Specific T Cell Responses in Hepatocellular Carcinoma (Eishiro Mizukoshi, Shuichi Kaneko)....Pages 39-50 Immune Checkpoint Inhibitors for the Treatment of Hepatocellular Carcinoma (Mercedes Iñarrairaegui, Delia D’Avola, Bruno Sangro)....Pages 51-68 Cytokine-Induced Killer Cells for the Adjuvant Treatment of Patients with HCC (Jeong-Hoon Lee, Jung-Hwan Yoon)....Pages 69-84 Anti-VEGFR Therapy as a Partner for Immune-Based Therapy Approaches in HCC (Kohei Shigeta, Tai Hato, Yunching Chen, Dan G. Duda)....Pages 85-101 Glypican-3 as a Target for Immune Based Therapy in Hepatocellular Carcinoma (Yi-Fan Zhang, Jessica Hong, Mitchell Ho)....Pages 103-119 Immune Suppressor Mechanisms in HCC (Tim F. Greten, Firouzeh Korangy)....Pages 121-135 Impact of Cytokines in Hepatocellular Carcinoma Initiation and Progression (Yeni Ait-Ahmed, Fouad Lafdil)....Pages 137-161 Back Matter ....Pages 163-167